{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-035365","form_type":"8-K","ticker":"LCTX","cik":"0000876343","company_name":"Lineage Cell Therapeutics, Inc.","filed_at":"2024-03-22T23:59:59+00:00","discovered_at":"2026-05-14T18:03:27.107895+00:00","generated_at":"2026-06-04T09:26:44.029921+00:00","sec_items":["1.01","8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Lineage Cell Therapeutics enters new ATM facility with B. Riley; FDA delays OPC1 study start","bullets":["Entered Sales Agreement with B. Riley Securities to sell up to $6.7M in common shares via at-the-market offering; 3% commission.","Terminated prior ATM with Cantor Fitzgerald; prior program sold approximately $6.66M in shares.","FDA review of OPC1 IND for spinal cord injury ongoing; requested not to initiate DOSED study until feedback expected by April 26, 2024.","Initial FDA clinical information request resolved; company aims to open first DOSED study site in Q2 2024.","No change to previously guided timeline for study initiation; no additional activities required to address FDA request."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-035365","json":"https://secwatch.observer/filing/0000950170-24-035365.json","markdown":"https://secwatch.observer/filing/0000950170-24-035365.md","text":"https://secwatch.observer/filing/0000950170-24-035365.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/876343/000095017024035365/0000950170-24-035365-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/876343/000095017024035365/lctx-20240312.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-04T09:26:44.029921+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"1001a82fd7f1263f6cd731e1f147456f85053132","claim":"Lineage Cell Therapeutics, Inc. entered into Sales Agreement with B. Riley Securities, Inc. (effective 2024-03-22).","evidence_excerpt":"on March 22, 2024, Lineage Cell Therapeutics, Inc. (the “Company” or “Lineage”), entered into a sales agreement (the “Sales Agreement”) with B. Riley Securities, Inc. (the “Sales Agent”), under which the Company may offer and sell its common shares from time to time through the Sales Agent as the Company’s sales agent.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/876343/000095017024035365/0000950170-24-035365-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"atm program"},{"label":"Counterparty","value":"B. Riley Securities, Inc."},{"label":"Effective","value":"2024-03-22"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}